Project Grant R01AI193216
Award Date 8/18/25
Completion Date 7/31/29
Dollars Obligated $3.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $147,486 to Emory University to develop novel methods for assessing the pandemic potential of influenza A viruses. The objectives are to: 1) Use data from animal model transmission studies to estimate key epidemiological parameters like the basic reproduction number and generation interval prior to human outbreaks; and 2) Apply...
- The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $390,942 Project Grant to the Georgia Tech Research Corporation on June 12, 2025. The goal of this grant is to use self-assembled protein nanocages (SAPNs) as a universal flu vaccine platform and evaluate/enhance its effectiveness. SAPNs will present multiple copies of three highly conserved influenza antigens - trimeric...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $147,486.00 to Emory University to conduct research on the beneficial effects of influenza A virus co-infection. The key products and services to be delivered include: Evaluating the density-dependence of discrete viral functions during the early life cycle of influenza A viruses, with a focus on how this dependence is impacted by antiviral...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop the L7AE protein as a therapeutic for treating Orthomyxoviridae family viral infections, such as influenza. The $3,170,096 award to New York University School of Medicine will fund a 4-year research project with the following key objectives: 1) Investigate the mechanism of action of L7AE on various Orthomyxoviridae family members to...
- This $146,922.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to define factors that modulate the efficiency of influenza A virus (IAV) infection. The project aims to investigate how the mode and circumstances of viral exposure, including route of infection (intranasal vs. aerosol) and environmental conditions (temperature, humidity), impact the efficiency of IAV transmission and...
- This Project Grant award, in the amount of $438,500, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective is to expand on prior research on the interactions between the influenza A virus (IAV) protein NS2 and the viral replication machinery, with the goal of better understanding sequence-specific determinants and impacts of these interactions. The research will be conducted at the...
- This $416,276 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) supports research to investigate factors that modulate Fc-mediated immune responses, with the goal of increasing the protective capacity of antibodies against influenza virus and Streptococcus pneumoniae. The 5-year project, awarded to the University of Georgia Research Foundation, Inc., aims to define...
- This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to define the structure-function relationships that regulate the functions of the influenza virus non-structural protein 1 (NS1) and nuclear export protein (NEP). This $587,885 award to the University of Alabama at Birmingham (UAB) will investigate the mechanisms by which NS1 and NEP govern the influenza...
- This $1,013,003 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the IND-enabling development of Inhalon Biopharma's IN-005, an inhaled muco-trapping monoclonal antibody (mAb) therapy against influenza A. The funding will advance Inhalon's pipeline of inhaled antiviral mAbs designed for direct delivery to the respiratory tract to achieve high local concentrations and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the Scripps Research Institute. The grant, with a performance period from January 23, 2025 to December 31, 2026, is funding research to develop a broad-spectrum influenza vaccine by targeting the neuraminidase (NA) protein. The research aims to design NA immunogens that can engage diverse broadly...